• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Biomarker Reveals Who Is at Highest Risk for Neuropathy


Biomarker research might reveal neuropathy risk with certain cancer therapies.

Researchers studying peripheral neuropathy—experienced to a significant degree by about one-third of cancer patients receiving taxane chemotherapy—have identified a genetic biomarker that could predict which patients are at greatest risk of developing the condition. Taxanes, although effective at destroying cancer cells, can do temporary or permanent damage to the peripheral nervous system.

“Unfortunately, there are no established biomarkers to predict which patients will experience this toxicity prior to receiving the drug,” says Bryan P. Schneider, MD, lead author and associate director for the Indiana Institute for Personalized Medicine at the Indiana University Melvin and Bren Simon Cancer Center. In the genome-wide association study of 2,204 patients on Taxol (paclitaxel), Schneider and his team looked for variations in inherited DNA called single nucleotide polymorphisms (SNPs) while evaluating more than 1.2 million SNPs in each patient.

They then identified genetic subgroups that were more likely to develop this adverse side effect. Older patients and African Americans were much more likely to develop peripheral neuropathy, according to the study, and further research in these groups is under way. The findings may lead to a simple blood test to determine whether a patient has a high risk of developing neuropathy, allowing for better counseling, use of alternative drugs or schedules, or omission of taxanes when appropriate.

Related Videos
A man with a dark gray button-up shirt with glasses and cropped brown hair.
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE